JP2007523168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523168A5 JP2007523168A5 JP2006554165A JP2006554165A JP2007523168A5 JP 2007523168 A5 JP2007523168 A5 JP 2007523168A5 JP 2006554165 A JP2006554165 A JP 2006554165A JP 2006554165 A JP2006554165 A JP 2006554165A JP 2007523168 A5 JP2007523168 A5 JP 2007523168A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pain
- use according
- compound
- migraine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 206010027599 Migraine Diseases 0.000 claims 3
- 208000008085 Migraine Disorders Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010002855 Anxiety Diseases 0.000 claims 2
- 206010057666 Anxiety disease Diseases 0.000 claims 2
- 206010015037 Epilepsy Diseases 0.000 claims 2
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 208000005298 Acute Pain Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002383 Angina pectoris Diseases 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000010374 Down syndrome Diseases 0.000 claims 1
- 208000001130 Gallstone Diseases 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000004559 Hearing Loss Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010020993 Hypoglycaemia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010027378 Mental retardation Diseases 0.000 claims 1
- 208000004296 Neuralgia Diseases 0.000 claims 1
- 206010064062 Neurodevelopmental disease Diseases 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010036376 Post herpetic neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000000399 Procedural Pain Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000002055 autistic disease Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 235000019788 craving Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000002146 gastrointestinal system disease Diseases 0.000 claims 1
- 201000005569 gout Diseases 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 230000001146 hypoxic Effects 0.000 claims 1
- 201000006347 intellectual disability Diseases 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004914 menses Anatomy 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 230000003340 mental Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000926 neurological Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (9)
- 有効成分として治療上有効な量の請求項1に記載の化合物を、1以上の薬学上許容される希釈剤、賦形剤および/または不活性担体と組み合わせて含んでなる医薬処方物。
- mGluR5受容体媒介疾患の予防および/または治療に使用するための薬剤の製造における、請求項1に記載の化合物の使用。
- ヒトにおけるmGluR5受容体媒介疾患の予防および/または治療の方法であって、こうした予防および/または治療を必要とする患者に、請求項1に記載の化合物の治療上有効な量を投与することを含んでなる、前記方法。
- 疾患が神経疾患である、請求項3に記載の使用。
- 疾患が精神疾患である、請求項3に記載の使用。
- 疾患が慢性疼痛疾患および急性疼痛疾患から選択される、請求項3に記載の使用。
- 疾患が消化管疾患である、請求項3に記載の使用。
- 疾患が、アルツハイマー病、老人性痴呆症、AIDS誘発型痴呆、パーキンソン病、筋萎縮性側索硬化症、ハンチントン舞踏病、片頭痛、癲癇、統合失調症、鬱病、不安症、急性不安症、強拍神経症、眼科疾患、糖尿病性網膜症、緑内障、聴覚障害、化学療法誘発性神経障害、疱疹後神経痛および三叉神経痛、耐性、依存性、常習性および渇望障害、神経発達障害、自閉症、精神遅滞、統合失調症、ダウン症候群、片頭痛に付随する疼痛、炎症性疼痛、神経痛疾患、関節炎およびリウマチ様疾患、腰痛、術後痛、アンギナに関連する疼痛、腎疝痛または胆石疝痛、月経、片頭痛、痛風、卒中、頭部外傷、低酸素および虚血性傷害、低血糖症、心血管疾患および癲癇から成る群より選択される、請求項3に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60896004P | 2004-02-18 | 2004-02-18 | |
US60/608,960 | 2004-02-18 | ||
PCT/US2005/004774 WO2006014185A1 (en) | 2004-02-18 | 2005-02-15 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007523168A JP2007523168A (ja) | 2007-08-16 |
JP2007523168A5 true JP2007523168A5 (ja) | 2008-03-27 |
JP4912157B2 JP4912157B2 (ja) | 2012-04-11 |
Family
ID=35447957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006554165A Expired - Fee Related JP4912157B2 (ja) | 2004-02-18 | 2005-02-15 | 追加の複素多環式化合物及びそれらの代謝調節型グルタミン酸受容体アンタゴニストとしての使用 |
Country Status (27)
Country | Link |
---|---|
US (6) | US7585881B2 (ja) |
EP (2) | EP2311830A1 (ja) |
JP (1) | JP4912157B2 (ja) |
CN (2) | CN1984907A (ja) |
AT (1) | ATE483706T1 (ja) |
AU (1) | AU2005270208A1 (ja) |
BR (1) | BRPI0507497A (ja) |
CA (1) | CA2555566A1 (ja) |
CY (1) | CY1110965T1 (ja) |
DE (1) | DE602005023963D1 (ja) |
DK (1) | DK1723144T3 (ja) |
ES (1) | ES2352110T3 (ja) |
HK (1) | HK1099285A1 (ja) |
HR (1) | HRP20100654T1 (ja) |
IL (1) | IL177394A0 (ja) |
NO (1) | NO20063599L (ja) |
NZ (1) | NZ548954A (ja) |
PL (1) | PL1723144T3 (ja) |
PT (1) | PT1723144E (ja) |
RS (1) | RS51516B (ja) |
RU (1) | RU2370495C2 (ja) |
SG (1) | SG146657A1 (ja) |
SI (1) | SI1723144T1 (ja) |
UA (1) | UA84318C2 (ja) |
UY (1) | UY28766A1 (ja) |
WO (1) | WO2006014185A1 (ja) |
ZA (1) | ZA200606551B (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101723941A (zh) * | 2002-08-09 | 2010-06-09 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑 |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
CN1942457A (zh) * | 2004-04-20 | 2007-04-04 | 默克公司 | 作为β-促分泌酶抑制剂用于阿尔茨海默氏病的治疗中的1,3,5-取代的苯基衍生化合物 |
JPWO2006080533A1 (ja) * | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | 3−アミノ−1,2,4−トリアゾール誘導体 |
AR058807A1 (es) * | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
WO2008014199A2 (en) * | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體2(mglu2 受體)之正向調節劑之雜環化合物 |
AU2008277730B2 (en) | 2007-07-13 | 2013-01-31 | Addex Pharma S.A. | Pyrazole derivatives as modulators of metabotropic glutamate receptors |
CN101896480A (zh) * | 2007-10-19 | 2010-11-24 | 阿斯利康(瑞典)有限公司 | 作为亲代谢性谷氨酸受体(mglurs)调节剂的四唑衍生物 |
WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
WO2009061652A1 (en) * | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
MX2010009732A (es) * | 2008-03-03 | 2010-09-30 | Stiefel Laboratories | Procedimientos para preparar compuestos de diol y dioxolano enantiomericamente puros. |
PT2913326T (pt) * | 2008-05-14 | 2020-08-24 | Scripps Research Inst | Novos moduladores de recetores de fosfato de esfingosina |
US8178568B2 (en) * | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
US20100041706A1 (en) * | 2008-08-12 | 2010-02-18 | Astrazeneca Ab | Compounds 501 |
CN102176910A (zh) * | 2008-08-12 | 2011-09-07 | 阿斯利康(瑞典)有限公司 | 4-(5-{(1r)-1-[5-(3-氯苯基)异噁唑-3-基]乙氧基}-4-甲基-4h-1,2,4-三唑-3-基)吡啶的新晶体形式 |
CA2737639A1 (en) * | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
US20110306768A1 (en) * | 2008-12-18 | 2011-12-15 | Astrazeneca Ab | Processes for the manufacture of 3--pyridine, 4-methyl-3-methylthio-5-(3-pyridyl)-l,2,4-triazole, and (1r)-1-[2-(3-methylphenyl)-2h-tetrazol-5-yl]ethanol |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
WO2010096371A2 (en) | 2009-02-18 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the cb2 receptor |
EP2414340A1 (en) * | 2009-04-03 | 2012-02-08 | Dainippon Sumitomo Pharma Co., Ltd. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
EP2438052A1 (en) * | 2009-06-05 | 2012-04-11 | Oslo University Hospital HF | Azole derivatives as wtn pathway inhibitors |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
EP2443107B1 (en) | 2009-06-16 | 2018-08-08 | Boehringer Ingelheim International GmbH | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
JP2013505295A (ja) * | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節する化合物 |
ES2858337T3 (es) * | 2009-11-13 | 2021-09-30 | Receptos Llc | Moduladores selectivos del receptor de fosfato de esfingosina 1 y métodos de síntesis quiral |
MX2012005562A (es) | 2009-11-13 | 2012-10-05 | Receptos Inc | Moduladores del receptor de esfingosina 1 fosfato y metodos de sintesis quiral. |
NZ599914A (en) * | 2009-11-13 | 2014-08-29 | Receptos Inc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
WO2011082010A1 (en) | 2009-12-29 | 2011-07-07 | Eli Lilly And Company | Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
CN101712641B (zh) * | 2009-12-29 | 2013-05-08 | 江苏工业学院 | 一种甲硫基苯甲酸的制备方法 |
JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
EP2542539B1 (en) | 2010-03-05 | 2014-02-26 | Boehringer Ingelheim International GmbH | Tetrazole compounds which selectively modulate the cb2 receptor |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
US20130203735A1 (en) * | 2010-10-28 | 2013-08-08 | John T. Sisko | Caprolactam mglur5 receptor modulators |
CN103429583A (zh) | 2010-12-08 | 2013-12-04 | 奥斯陆大学医院公司 | 作为wnt信号通路抑制剂的三唑衍生物 |
DE102010063974B4 (de) * | 2010-12-22 | 2021-10-07 | Thomas Rühl | Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung |
WO2012127393A1 (en) | 2011-03-18 | 2012-09-27 | Novartis Ag | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE |
US8759380B2 (en) * | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
ES2758841T3 (es) | 2011-05-13 | 2020-05-06 | Celgene Int Ii Sarl | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
SG11201601682RA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazole derivatives as immunomodulators |
BR112017018992B1 (pt) * | 2015-03-05 | 2022-02-08 | Bayer Cropscience Aktiengesellschaft | Processo de preparação de derivados de fenilisoxazolina substituída |
MX2017011612A (es) * | 2015-03-10 | 2018-03-23 | Aurigene Discovery Tech Ltd | Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores. |
CN114213356A (zh) | 2015-03-10 | 2022-03-22 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物 |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
EP3730487B1 (en) | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidine derivatives as fxr (nr1h4) modulators |
PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
IL272838B2 (en) | 2017-10-06 | 2023-09-01 | Forma Therapeutics Inc | Peptidase-specific ubiquitin inhibition 30 |
SG11202003081WA (en) | 2017-10-11 | 2020-05-28 | Aurigene Discovery Tech Ltd | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
WO2019087087A1 (en) | 2017-11-03 | 2019-05-09 | Aurigene Discovery Technologies Limited | Dual inhibitors of tim-3 and pd-1 pathways |
EP3706798A1 (en) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
WO2019095046A1 (en) * | 2017-11-16 | 2019-05-23 | Montdorex Inc. | Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity |
SG11202011299PA (en) | 2018-05-17 | 2020-12-30 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
PE20211053A1 (es) | 2018-10-05 | 2021-06-07 | Forma Therapeutics Inc | Inhibicion de la proteasa 30 especifica de la ubiquitina (usp30) |
SI3911647T1 (sl) | 2019-01-15 | 2024-04-30 | Gilead Sciences, Inc. | Izoksazolna spojina kot agonist FXR in farmacevtski sestavki, ki jo obsegajo |
JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | Fxrアゴニストの固体形態 |
MX2021013421A (es) * | 2019-05-03 | 2022-02-11 | Praxis Prec Medicines Inc | Inhibidores de kcnt1 y metodos de uso. |
KR20220164471A (ko) * | 2020-01-07 | 2022-12-13 | 디스암 테라퓨틱스, 인크. | Sarm1의 억제제 |
TW202334117A (zh) | 2020-08-24 | 2023-09-01 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
WO2022231872A1 (en) * | 2021-04-29 | 2022-11-03 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4538833A (en) * | 1983-12-08 | 1985-09-03 | P I E International Inc. | Publication |
US5403138A (en) * | 1991-10-09 | 1995-04-04 | Fuji Photo Film Co., Ltd. | Booklet album including a double-sided photograph and a method of making the same |
US5332265A (en) * | 1993-01-22 | 1994-07-26 | Minnesota Mining And Manufacturing Company | Advertising assembly |
AU780191B2 (en) | 1999-08-19 | 2005-03-03 | Astrazeneca Ab | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
JP2005516950A (ja) | 2001-12-19 | 2005-06-09 | メルク エンド カムパニー インコーポレーテッド | 代謝型グルタミン酸受容体−5のヘテロアリール置換イミダゾールモジュレータ |
CN101723941A (zh) * | 2002-08-09 | 2010-06-09 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的“1,2,4”二唑 |
AU2003264018A1 (en) * | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
TW200812986A (en) | 2002-08-09 | 2008-03-16 | Nps Pharma Inc | New compounds |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
AR058807A1 (es) * | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
-
2005
- 2005-02-09 US US11/053,752 patent/US7585881B2/en not_active Expired - Fee Related
- 2005-02-15 NZ NZ548954A patent/NZ548954A/xx unknown
- 2005-02-15 AT AT05802855T patent/ATE483706T1/de active
- 2005-02-15 US US10/588,702 patent/US20070179188A1/en not_active Abandoned
- 2005-02-15 PL PL05802855T patent/PL1723144T3/pl unknown
- 2005-02-15 SI SI200531175T patent/SI1723144T1/sl unknown
- 2005-02-15 WO PCT/US2005/004774 patent/WO2006014185A1/en active Application Filing
- 2005-02-15 EP EP10182161A patent/EP2311830A1/en not_active Withdrawn
- 2005-02-15 CN CNA2005800043063A patent/CN1984907A/zh active Pending
- 2005-02-15 ES ES05802855T patent/ES2352110T3/es active Active
- 2005-02-15 CN CNA2007101278476A patent/CN101096368A/zh active Pending
- 2005-02-15 PT PT05802855T patent/PT1723144E/pt unknown
- 2005-02-15 BR BRPI0507497-5A patent/BRPI0507497A/pt not_active IP Right Cessation
- 2005-02-15 AU AU2005270208A patent/AU2005270208A1/en not_active Abandoned
- 2005-02-15 EP EP05802855A patent/EP1723144B1/en active Active
- 2005-02-15 UA UAA200608867A patent/UA84318C2/ru unknown
- 2005-02-15 DK DK05802855.6T patent/DK1723144T3/da active
- 2005-02-15 RU RU2006128446/04A patent/RU2370495C2/ru not_active IP Right Cessation
- 2005-02-15 JP JP2006554165A patent/JP4912157B2/ja not_active Expired - Fee Related
- 2005-02-15 CA CA002555566A patent/CA2555566A1/en not_active Abandoned
- 2005-02-15 DE DE602005023963T patent/DE602005023963D1/de active Active
- 2005-02-15 SG SG200806914-8A patent/SG146657A1/en unknown
- 2005-02-15 RS RSP-2010/0525A patent/RS51516B/en unknown
- 2005-02-18 UY UY28766A patent/UY28766A1/es not_active Application Discontinuation
-
2006
- 2006-08-07 ZA ZA200606551A patent/ZA200606551B/en unknown
- 2006-08-08 NO NO20063599A patent/NO20063599L/no not_active Application Discontinuation
- 2006-08-09 IL IL177394A patent/IL177394A0/en unknown
-
2007
- 2007-05-22 HK HK07105399.9A patent/HK1099285A1/xx not_active IP Right Cessation
- 2007-08-18 US US11/840,952 patent/US20080015234A1/en not_active Abandoned
- 2007-08-18 US US11/840,954 patent/US20070293545A1/en not_active Abandoned
- 2007-08-18 US US11/840,953 patent/US20080045571A1/en not_active Abandoned
- 2007-08-18 US US11/840,955 patent/US20080015204A1/en not_active Abandoned
-
2010
- 2010-11-29 HR HR20100654T patent/HRP20100654T1/hr unknown
- 2010-12-03 CY CY20101101116T patent/CY1110965T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007523168A5 (ja) | ||
RU2006128446A (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
JP2009510064A5 (ja) | ||
RU2008108219A (ru) | Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств | |
JP2021075566A5 (ja) | ||
JP2007504174A5 (ja) | ||
JP2023002846A5 (ja) | ||
JP2008534627A5 (ja) | ||
JP2010505958A5 (ja) | ||
JP2007145875A5 (ja) | ||
JP2009500443A5 (ja) | ||
JP2005506370A5 (ja) | ||
EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
JP2011500673A5 (ja) | ||
JP2009510044A5 (ja) | ||
JP2019524865A5 (ja) | ||
WO2009008006A3 (en) | Pharmaceutical compositions for gastrointestinal drug delivery | |
JP2011522816A5 (ja) | ||
RU2008116931A (ru) | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей | |
WO2012009258A3 (en) | Peptidomimetic galanin receptor modulators | |
JP2008007519A5 (ja) | ||
JP2010529203A5 (ja) | ||
JP2007533687A5 (ja) | ||
WO2004041245B1 (en) | Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases | |
RU2014112370A (ru) | Фармацевтическая композиция для применения при лечении нейродегенеративного заболевания |